3,7,12-Trioxo-cholansaeuremethylester | 7727-82-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3,7,12-Trioxo-cholansaeuremethylester
• 英文别名: methyl 4-[(5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-3,7,12-trioxo-1,2,4,5,6,8,9,11,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pentanoate
• CAS: 7727-82-4；15074-09-6；55555-42-5
• 化学式: C₂₅H₃₆O₅
• 分子量: 416.558
• InChiKey: ZNRVRJLOYAQJBW-ADCPSXKASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  77.5
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• LATENT ACIDS AND THEIR USE
  申请人：BASF SE

  公开号：EP2539316B1

  公开（公告）日：2019-10-23
• Methods and pharmaceutical formulations for increasing bioavailability
  申请人：Wempe F. Michael

  公开号：US20070060610A1

  公开（公告）日：2007-03-15

  This invention relates to methods and compositions for increasing the bioavailability of pharmaceutical or lipophilic compounds. The invention further relates of methods of administering the compounds and compositions of the present invention to a human or animal.
• Compounds exhibiting efflux inhibitor activity and composition and uses thereof
  申请人：Wempe Fitzpatrick Michael

  公开号：US20070254859A1

  公开（公告）日：2007-11-01

  At least one compound chosen from compounds of Formula I: a pharmaceutically acceptable salt or ester thereof, a solvate thereof, a chelate thereof, a non-covalent complex thereof, a prodrug thereof, and mixtures of any of the foregoing, wherein: n is a number from 1 to 900, wherein the individual units may be the same or different; W is chosen from alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; each of R 2 , R 3 , R 4 and R 5 is independently chosen from —H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; Z′ is chosen from —O—, —N—, —NO—, —NR 4 —, —S—, —SO— and —SO 2 —, wherein R 4 is defined as above; each of X, X′, Y and Z is independently chosen from —CR 4 R 5 —, —NH—, —NR 4 —, —NO—, —O—, —NOR 4 —, —S—, —SO—, —SO 2 —, wherein R 4 and R 5 are defined as above; R 1 is chosen from a tocopherol, a steroid and a flavonoid; and R 6 is chosen from any R 1 , alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl.